Anti-angiogenic activity of basic-type, selective cyclooxygenase (COX)-1 inhibitors
Authors:
- Hiroyuki MiyachiHMHiroyuki Miyachi
- 1 June 2006
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (11) , 3068-3072
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 13 references indexed in Scilit:
- Combined effects of cyclooxygenase‐1 and cyclooxygenase‐2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout miceInternational Journal of Cancer, 2004
- Thalidomide and its analogues as cyclooxygenase inhibitorsBioorganic & Medicinal Chemistry Letters, 2002
- Thalidomide: Emerging Role in Cancer MedicineAnnual Review of Medicine, 2002
- Why there are two cyclooxygenase isozymesJournal of Clinical Investigation, 2001
- Thalidomide: current and potential clinical applicationsThe American Journal of Medicine, 2000
- Thalidomide on the comeback trailNature Medicine, 1999
- COX-2 inhibitorsThe Lancet, 1999
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Towards a better aspirinNature, 1994
- Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoidsNeuron, 1993